ADRO Aduro Biotech Inc.

3.15
-0.23  -7%
Previous Close 3.38
Open 3.32
Price To Book 1.86
Market Cap 251533942
Shares 79,852,045
Volume 166,159
Short Ratio
Av. Daily Volume 477,030

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 poster at ASCO June 3, 2019, 8:00AM.
BION-1301
Multiple Myeloma
Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
ADU-S100
Solid tumors or lymphomas
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Noted December 12, 2017 that development to be discontinued.
CRS-207 with pembrolizumab
Mesothelioma - cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1b initiation announced June 7, 2018.
ADU-214 with Nivolumab
Non-Small Cell Lung Cancer
Phase 1b presentation at ASCO June 2, 2019, 8:00 AM.
ADU-S100 and Spartalizumab
Solid tumors or lymphomas
Phase 1 commencement of dosing announced February 11, 2019.
ADU-S100 and ipilimumab
Melanoma

Latest News

  1. Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
  2. Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
  3. Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer
  4. Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
  5. Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
  6. What Kind Of Shareholders Own Aduro BioTech, Inc. (NASDAQ:ADRO)?
  7. Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference
  8. Lilly (LLY) Signs New Immunology Deal With Private Biotech
  9. Aduro Biotech to Present at Two Upcoming Investor Conferences in March
  10. The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
  11. What Should We Expect From Aduro BioTech, Inc.’s (NASDAQ:ADRO) Earnings In The Years Ahead?
  12. Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
  13. Top Ranked Momentum Stocks to Buy for February 28th
  14. Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019
  15. Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
  16. Will Aduro Biotech Continue to Surge Higher?
  17. What's in Store for Universal Health (UHS) Q4 Earnings?
  18. What's in Store for Vericel (VCEL) This Earnings Season?
  19. Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
  20. Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference